Adipotide vs Semaglutide
| Attribute | Adipotide FTPP | Semaglutide GLP-1 receptor agonist |
|---|---|---|
| Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
| Best known for | Targeted fat-cell apoptosis research | Weight loss and blood sugar research |
| In plain English | It's designed to find the blood vessels feeding fat tissue and shut them down. | Semaglutide mimics the hormone your gut releases when you eat. The brain reads it as 'we're full,' appetite drops, and stomach emptying slows down. |
| How it works | The homing domain targets prohibitin on white-adipose vasculature; the KLAKLAK domain triggers mitochondrial apoptosis, starving fat tissue. | Activates the GLP-1 receptor in the pancreas, brain, and gut — increasing insulin secretion, slowing gastric emptying, and reducing appetite through hypothalamic signaling. |
| Researchers study | Obesity models in primates; documented rapid fat loss with renal-toxicity concerns. | Glycemic control, weight reduction, cardiovascular outcomes, and emerging research in addiction and neuroinflammation. |
| Internet discussion | Discussed as the 'kills fat cells' peptide; almost always paired with strong warnings about kidney signals. | The internet talks about semaglutide constantly — 'Ozempic face,' food noise reduction, alcohol cravings dropping, and dose-titration questions. |
Adipotide
Targeted fat-cell apoptosis research
It's designed to find the blood vessels feeding fat tissue and shut them down.
The homing domain targets prohibitin on white-adipose vasculature; the KLAKLAK domain triggers mitochondrial apoptosis, starving fat tissue.
Obesity models in primates; documented rapid fat loss with renal-toxicity concerns.
Discussed as the 'kills fat cells' peptide; almost always paired with strong warnings about kidney signals.
Adipotide is an experimental peptide researched for targeted destruction of fat-tissue blood supply.
Semaglutide
Weight loss and blood sugar research
Semaglutide mimics the hormone your gut releases when you eat. The brain reads it as 'we're full,' appetite drops, and stomach emptying slows down.
Activates the GLP-1 receptor in the pancreas, brain, and gut — increasing insulin secretion, slowing gastric emptying, and reducing appetite through hypothalamic signaling.
Glycemic control, weight reduction, cardiovascular outcomes, and emerging research in addiction and neuroinflammation.
The internet talks about semaglutide constantly — 'Ozempic face,' food noise reduction, alcohol cravings dropping, and dose-titration questions.
Semaglutide is the reference GLP-1 agonist — well-studied for blood sugar control and significant weight reduction.